Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts. Show more
Location: 75 State Street, Boston, MA, 02109, United States | Website: https://www.finchtherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
20.1M
52 Wk Range
$1.27 - $15.85
Previous Close
$12.75
Open
$12.75
Volume
305
Day Range
$12.75 - $12.75
Enterprise Value
34.15M
Cash
16.04M
Avg Qtr Burn
-4.514M
Insider Ownership
13.39%
Institutional Own.
0.47%
Qtr Updated
06/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CP101 Details Ulcerative colitis | Phase 1/2 Data readout | |
CP101 Details Clostridioides difficile infection | Failed Discontinued |